DBD vs TMO · P/E 28, rev $3.75B vs P/E 24, rev $44.56B
Diebold Nixdorf, Incorporated (DBD) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Diebold Nixdorf, Incorporated (DBD) is a software - application company listed on US.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported DBD revenue for 2024-12-31 was $3.75B. Net income was -$14.5M. Revenue was up 130.3% from 2023-12-31 to 2024-12-31. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
DBD currently screens at market cap $2.82B and trailing P/E 28.1. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the DBD and TMO stock pages for the full models.
Not investment advice.